Statins are primarily prescribed for:
If you already have cardiovascular disease, your doctor may recommend statins to reduce your risk of having a heart attack or stroke. Statin therapy may also be prescribed if you fall within a specific risk range for developing cardiovascular disease within 10-years. The risk can be assessed based on your cholesterol numbers and other risk factors. It can be done during a regular physical exam.
HMG-CoA reductase is an enzyme that helps your body make cholesterol. Statins help to block this enzyme, which in turn causes your body to make less cholesterol. When you make less cholesterol, your liver makes more LDL receptors, which attract LDL particles in the blood. This reduces the amount of LDL ("bad") cholesterol in your bloodstream. Lower LDL cholesterol levels also tend to lead to lower levels of triglycerides and higher HDL (“good”) cholesterol levels in the blood. Statins have anti-inflammatory effects on blood vessels which help reduce the formation of fatty plaque on blood vessel walls.
Statins can interact with many medications. Below are some examples. But, you should talk to your doctor and pharmacist about the specific medications that you are taking.
Statins can interact with certain foods, herbs, and supplements. Here are examples of potential interactions:
If you would like to take herbs or supplements while taking a statin, check with your doctor first.
These conditions can affect how your body uses statins:
If you have any of the following conditions, tell your doctor before you are prescribed statins:
More common side effects include:
Less common, but more serious side effects include:
American Heart Association
US Food and Drug Administration
Heart and Stroke Foundation of Canada
Amarenco P, Bogousslavsky J, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
Grundy SM, Cleeman JL, et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Circulation. 2004;110:227-239.
Lemaitre RN, Psaty B, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults. Arch Intern Med. 2002;162:1395-1400.
Lipid-lowering pharmacotherapy overview. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated September 12, 2014. Accessed December 11, 2014.
Middleton A, Binbrek AS, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6,743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin. 2006;22: 1181-1191.
Statins. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated November 4, 2014. Accessed December 11, 2014.
Statins. Food and Drug Administration website. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm. Updated November 21, 2012. Accessed December 11, 2014.
Statin drugs. EBSCO Natural and Alternative Treatments website. Available at: http://www.ebscohost.com/biomedical-libraries/natural-alternative-treatments. Updated September 18, 2014. Accessed December 11, 2014.
Statins for prevention of cardiovascular disease. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated September 15, 2014. Accessed December 11, 2014.
Stender S, Schuster H, et al. Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7:430-438.
Tahara N, Kai H, et al. Simvastatin attenuates plaque inflammation: evaluation by fuorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-1831.
1/30/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Mills EJ, Rachlis B, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.
3/6/2012 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: FDA announces safety changes in labeling for some cholesterol-lowering drugs. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. Updated March 2, 2012. Accessed December 11, 2014.
Last reviewed December 2014 by Michael Woods, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2012 EBSCO Publishing All rights reserved.
What can we help you find?close ×